Tag: psoriatic arthritis

All

The federal Food and Drug Administration has given its nod to Otezla (apremilast) for the treatment of adults with active psoriatic arthritis (PsA).

Study results presented at EADV 2025 show nearly half of initial complete responders maintained clearance over four years.